Abingdon Health (ABDX) Share Price, News & Analysis

Company Overview

Abingdon Health is a world leading contract developer and manufacturer (CDMO) of high-quality rapid tests across all industry sectors, including healthcare, infectious disease, animal health, environmental and self-testing. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and regulatory approval. The Company also markets its own range of self-tests under the Abingdon Simply Test brand (www.abingdonsimplytest.com) and has developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology and algorithm that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.

Key Stats

• Today's Range: 7.36 to 8.50
• 50-Day Range: 7.06 to 8.50
• 52-Week Range: 6.50 to 11.75
• Volume: 263,873 shs
• Average Volume: 155,350 shs
• Market Capitalization: £16.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ABDX Stock Analysis - Frequently Asked Questions

How have ABDX shares performed this year?

Abingdon Health's stock was trading at GBX 7.92 at the start of the year. Since then, ABDX stock has increased by 7.3% and is now trading at GBX 8.50.
View the best growth stocks for 2025 here.

How were Abingdon Health's earnings last quarter?

Abingdon Health Plc (LON:ABDX) announced its quarterly earnings data on Tuesday, October, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter. Abingdon Health had a negative net margin of 20.72% and a negative trailing twelve-month return on equity of 48.69%.

How do I buy shares of Abingdon Health?

Shares of ABDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Abingdon Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abingdon Health investors own include 4D pharma (DDDD), genedrive (GDR), Novacyt (NCYT), Rolls-Royce Holdings plc (RR.L), Tullow Oil (TLW), Active Energy Group (AEG) and B&M European Value Retail (BME).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:ABDX
• CUSIP: N/A
• CIK: N/A
• Web: www.abingdonhealth.com
• Phone: 44 19 0440 6082
• Fax: N/A
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,270,000.00
• Net Margins: -20.72%
• Pretax Margin: N/A
• Return on Equity: -48.69%
• Return on Assets: -17.93%

Debt

• Debt-to-Equity Ratio: 46.64
• Current Ratio: 1.95
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: £6.13 million
• Price / Sales: 2.63
• Cash Flow: GBX 3.78 per share
• Price / Cash Flow: 2.25
• Book Value: GBX 1 per share
• Price / Book: 8.50

Miscellaneous

• Outstanding Shares: 189,520,000
• Free Float: N/A
• Market Cap: £16.11 million
• Optionable: Not Optionable
• Beta: 0.13